BioRay's ROR1-Targeting Dual-Epitope ADC Drug BR111 Receives Formal Clinical Trial Approval from NMPA
SHANGHAI,Feb. 10,2025-- On December 19,2024,BioRay Pharmaceutical Co.,Ltd. ("BioRay") announced that the National Medical Products Administration (NMPA) has accepted the clinical trial appli